PT2326665E - Proteínas de fusão não citotóxicas compreendendo muteínas de egf - Google Patents
Proteínas de fusão não citotóxicas compreendendo muteínas de egfInfo
- Publication number
- PT2326665E PT2326665E PT97855027T PT09785502T PT2326665E PT 2326665 E PT2326665 E PT 2326665E PT 97855027 T PT97855027 T PT 97855027T PT 09785502 T PT09785502 T PT 09785502T PT 2326665 E PT2326665 E PT 2326665E
- Authority
- PT
- Portugal
- Prior art keywords
- fusion proteins
- egf
- cancer
- suppressing
- cytotoxic fusion
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 3
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 231100000065 noncytotoxic Toxicity 0.000 title abstract 2
- 230000002020 noncytotoxic effect Effects 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 102000001301 EGF receptor Human genes 0.000 abstract 1
- 108060006698 EGF receptor Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002124 endocrine Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 210000003097 mucus Anatomy 0.000 abstract 1
- 230000009826 neoplastic cell growth Effects 0.000 abstract 1
- 208000015706 neuroendocrine disease Diseases 0.000 abstract 1
- 201000011519 neuroendocrine tumor Diseases 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0815264.7A GB0815264D0 (en) | 2008-08-21 | 2008-08-21 | Non-cytotoxic proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2326665E true PT2326665E (pt) | 2013-12-23 |
Family
ID=39812369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT97855027T PT2326665E (pt) | 2008-08-21 | 2009-08-19 | Proteínas de fusão não citotóxicas compreendendo muteínas de egf |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8614069B2 (https=) |
| EP (1) | EP2326665B1 (https=) |
| JP (1) | JP5658152B2 (https=) |
| DK (1) | DK2326665T3 (https=) |
| ES (1) | ES2436816T3 (https=) |
| GB (1) | GB0815264D0 (https=) |
| PL (1) | PL2326665T3 (https=) |
| PT (1) | PT2326665E (https=) |
| WO (1) | WO2010020811A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9617671D0 (en) * | 1996-08-23 | 1996-10-02 | Microbiological Res Authority | Recombinant toxin fragments |
| US8790897B2 (en) * | 1998-08-25 | 2014-07-29 | Syntaxin Ltd. | Treatment of mucus hypersecretion |
| JP5799397B2 (ja) | 2008-06-12 | 2015-10-28 | イプセン・バイオイノベーション・リミテッドＩｐｓｅｎ Ｂｉｏｉｎｎｏｖａｔｉｏｎ Ｌｉｍｉｔｅｄ | 癌の抑制 |
| AU2011323832B2 (en) * | 2010-10-25 | 2016-06-02 | Niiki Pharma Inc. | Method of treating neuroendocrine tumors |
| KR101519118B1 (ko) * | 2013-07-23 | 2015-05-12 | (주)피앤피바이오팜 | 고안정성 상피세포 성장인자 변이체 |
| WO2016156468A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| HK1250011A1 (zh) * | 2015-03-31 | 2018-11-23 | Sorriso Pharmaceuticals, Inc. | 具有蛋白酶可切割接头的肽构建体 |
| DK3277719T3 (da) | 2015-03-31 | 2022-05-02 | Sorriso Pharmaceuticals Inc | Polypeptider |
| TW201814045A (zh) | 2016-09-16 | 2018-04-16 | 英商艾普森生物製藥有限公司 | 製造雙鏈梭狀芽孢桿菌神經毒素之方法 |
| WO2018060351A1 (en) | 2016-09-29 | 2018-04-05 | Ipsen Biopharm Limited | Hybrid neurotoxins |
| EP3519438A1 (en) | 2016-09-30 | 2019-08-07 | VHsquared Limited | Compositions |
| EP3312290A1 (en) | 2016-10-18 | 2018-04-25 | Ipsen Biopharm Limited | Cellular vamp cleavage assay |
| US11241480B2 (en) * | 2017-01-26 | 2022-02-08 | Washington University | Methods for modulation of dietary and microbial exposure with compositions comprising an EGFR ligand |
| UA128185C2 (uk) | 2018-01-29 | 2024-05-01 | Іпсен Біофарм Лімітед | Ботулінічний нейротоксин, який розщеплює ненейронний snare |
| GB201815817D0 (en) * | 2018-09-28 | 2018-11-14 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising and exogenous activation loop |
| GB201900621D0 (en) * | 2019-01-16 | 2019-03-06 | Ipsen Biopharm Ltd | Labelled polypeptides |
| WO2020219599A1 (en) * | 2019-04-23 | 2020-10-29 | Aurora Oncology | Compositions and methods for treatment of distentable tissues |
| KR20220063148A (ko) | 2019-06-21 | 2022-05-17 | 소리소 파마슈티컬스 인크. | 조성물 |
| WO2020254827A1 (en) | 2019-06-21 | 2020-12-24 | Vhsquared Limited | Polypeptides |
| JP7680377B2 (ja) | 2019-06-21 | 2025-05-20 | ソリッソ ファーマシューティカルズ，インク． | ポリペプチド |
| WO2024249812A2 (en) * | 2023-06-01 | 2024-12-05 | Blaze Bioscience, Inc. | Egf variants and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8003A (en) * | 1851-03-25 | Improvement in scythe-tastenings | ||
| GB9818548D0 (en) * | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
| US8790897B2 (en) * | 1998-08-25 | 2014-07-29 | Syntaxin Ltd. | Treatment of mucus hypersecretion |
| US20080038274A1 (en) * | 1999-09-23 | 2008-02-14 | Foster Keith A | Inhibition of secretion from non-neuronal cells |
| US7037504B2 (en) | 2001-10-23 | 2006-05-02 | Waratah Pharmaceuticals, Inc. | Epidermal growth factor protein and gene, and methods of use therefor |
| EP1479693A4 (en) | 2002-02-05 | 2005-07-27 | Japan Science & Tech Agency | EGF / EGFR COMPLEX |
| WO2007109673A2 (en) * | 2006-03-20 | 2007-09-27 | Stanford University | Mutant epidermal growth factor polypeptides, nucleic acids, and uses therefor |
| GB0725321D0 (en) | 2007-12-31 | 2008-02-06 | Syntaxin Ltd | Delivery vehicles |
-
2008
- 2008-08-21 GB GBGB0815264.7A patent/GB0815264D0/en not_active Ceased
-
2009
- 2009-08-19 WO PCT/GB2009/051036 patent/WO2010020811A1/en not_active Ceased
- 2009-08-19 ES ES09785502.7T patent/ES2436816T3/es active Active
- 2009-08-19 JP JP2011523457A patent/JP5658152B2/ja not_active Expired - Fee Related
- 2009-08-19 PT PT97855027T patent/PT2326665E/pt unknown
- 2009-08-19 DK DK09785502.7T patent/DK2326665T3/da active
- 2009-08-19 PL PL09785502T patent/PL2326665T3/pl unknown
- 2009-08-19 EP EP09785502.7A patent/EP2326665B1/en active Active
- 2009-08-19 US US13/059,695 patent/US8614069B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2436816T3 (es) | 2014-01-07 |
| PL2326665T3 (pl) | 2014-03-31 |
| US20110177056A1 (en) | 2011-07-21 |
| EP2326665B1 (en) | 2013-10-09 |
| JP2012500018A (ja) | 2012-01-05 |
| GB0815264D0 (en) | 2008-09-24 |
| EP2326665A1 (en) | 2011-06-01 |
| JP5658152B2 (ja) | 2015-01-21 |
| WO2010020811A1 (en) | 2010-02-25 |
| US8614069B2 (en) | 2013-12-24 |
| DK2326665T3 (da) | 2013-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2326665E (pt) | Proteínas de fusão não citotóxicas compreendendo muteínas de egf | |
| IL243812A0 (en) | Compounds of diarylhydantoin | |
| AR061245A1 (es) | Composiciones y metodos para la modulacion del desarrollo vascular | |
| MX2010000465A (es) | Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores. | |
| WO2005079844A3 (en) | Use for interleukin-33 (il33) and the il-33 receptor complex | |
| NZ713641A (en) | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b | |
| CY1119217T1 (el) | Ενωση για την αγωγη του καρκινου | |
| NZ606195A (en) | Methods and compositions for liver cancer therapy | |
| MX2016009070A (es) | Conjugados de anticuerpo-farmaco (adc) de duocarmicina que muestran actividad antitumoral in vivo mejorada. | |
| MY159135A (en) | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof | |
| NZ598127A (en) | Cancer metastasis inhibitor | |
| ECSP099523A (es) | Antagonistas específicos de VEGF para terapia adyuvante y neoadyuvante y el tratamiento de tumores en estadíos tempranos | |
| TW200618808A (en) | Methods for treating diverse cancers | |
| EP3680253A3 (en) | Therapeutic dll4 binding proteins | |
| EA201300411A1 (ru) | Конъюгаты антитело-лекарственное средство (adc), связывающиеся с белками 191p4d12 | |
| MY156315A (en) | Anti-vegf antibodies | |
| WO2007101235A3 (en) | Improved antitumoral treatments | |
| MX2009003778A (es) | Alimentacion a largo plazo para paciente de cancer. | |
| PH12012502044A1 (en) | Robo1-fc fusion protein and use thereof for treating tumours | |
| JO2833B1 (en) | Amino pyrazole compound | |
| MX2015015115A (es) | Metodos de tratamiento de cancer. | |
| AR075982A1 (es) | Terapia de combinacion de un anticuerpo afucosilado y una o mas de las citoquinas seleccionadas de gm- csf humano, m -csf humano y/o il-3 humano y composicion | |
| WO2007056049A3 (en) | Molecular profiling of cancer | |
| ES2422429T3 (es) | Diagnóstico del cáncer de próstata | |
| WO2011051271A3 (en) | Prostate tumor markers and methods of use thereof |